![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1475, 2005-01, pp. : 12-12
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel + cisplatin active in advanced NSCLC
Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cisplatin + pemetrexed as first-line therapy for advanced NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Gemcitabine plus pemetrexed promising in advanced NSCLC
Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Gemcitabine plus cisplatin for NSCLC
Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. :